Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes. 2010

Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
INSERM U620, Université de Rennes 1, F-35043, France.

Oltipraz, a synthetic derivative of the cruciferous vegetable product 1,2-dithiole-3-thione, is considered as a potent chemoprotectant. Previously, we have demonstrated that CYP2B6 expression is induced in cultured human hepatocytes by a 24h treatment with oltipraz. The aim of this study was to further determine mechanisms involved in the regulation of CYP2B6 by this compound. An increase of CYP2B6 mRNA is observed after a 4h exposure and maximum induction is reached after 24h. The rapid induction of CYP2B6 mRNA in oltipraz-treated cells suggests a transcriptional activation of corresponding gene. To test this hypothesis, we performed transient transfections with constructs containing the CYP2B6 gene 5'-flanking region upstream of the luciferase gene in order to measure the transcriptional activity of CYP2B6 gene in human hepatoma HepG2 cells, in absence or presence of oltipraz. The results demonstrate that transcriptional activation of CYP2B6 gene is mediated mainly by the pregnane X receptor (PXR) and the Phenobarbital Responsive Element Module (PBREM). The nuclear factor-erythroid 2-related factor 2 (Nrf2) and an antioxidant responsive element (ARE), located upstream the PBREM, might also have a role in this activation but their involvement remains unclear. Despite increasing CYP2B6 apoprotein levels in human hepatocytes, oltipraz has little effect, if any, on testosterone 16beta-hydroxylation which is catalyzed by CYP2B6. This can be explained by a dose-dependent inhibition of CYP2B6 activity in presence of oltipraz as demonstrated with human hepatocyte microsomes. Altogether, this study provides the first demonstration of PXR involvement in oltipraz transcriptional activation of CYP2B6 gene and of the inhibitory effect of oltipraz on CYP2B6 activity.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D010089 Oxidoreductases, N-Demethylating N-Demethylase,N-Demethylases,Oxidoreductases, N Demethylating,Demethylating Oxidoreductases, N,N Demethylase,N Demethylases,N Demethylating Oxidoreductases,N-Demethylating Oxidoreductases
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D011987 Receptors, Steroid Proteins found usually in the cytoplasm or nucleus that specifically bind steroid hormones and trigger changes influencing the behavior of cells. The steroid receptor-steroid hormone complex regulates the transcription of specific genes. Corticosteroid Receptors,Receptors, Corticosteroid,Steroid Receptors,Corticosteroid Receptor,Receptors, Steroids,Steroid Receptor,Receptor, Corticosteroid,Receptor, Steroid,Steroids Receptors
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D000077297 Pregnane X Receptor Steroid receptor that binds and is activated by variety of endogenous compounds and XENOBIOTICS. It binds the response element in promoters of genes that encode CYTOCHROME P450 3A4 and ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 proteins, and also activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs, and endogenous compounds. It is activated by the antibiotic RIFAMPICIN and various plant metabolites, such as hyperforin, guggulipid, colupulone, and ISOFLAVONES. NR1I2,Nuclear Receptor Subfamily 1, Group I, Member 2,SXR Receptor,Steroid X Receptor,Steroid and Xenobiotic Receptor
D001189 Aryl Hydrocarbon Hydroxylases A large group of cytochrome P-450 (heme-thiolate) monooxygenases that complex with NAD(P)H-FLAVIN OXIDOREDUCTASE in numerous mixed-function oxidations of aromatic compounds. They catalyze hydroxylation of a broad spectrum of substrates and are important in the metabolism of steroids, drugs, and toxins such as PHENOBARBITAL, carcinogens, and insecticides. Microsomal Monooxygenases,Xenobiotic Monooxygenases,Hydroxylases, Aryl Hydrocarbon,Monooxygenases, Microsomal,Monooxygenases, Xenobiotic

Related Publications

Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
September 2001, Molecular pharmacology,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
May 2003, Drug metabolism and disposition: the biological fate of chemicals,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
August 2000, Molecular pharmacology,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
March 2018, Drug metabolism and disposition: the biological fate of chemicals,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
January 2003, Drug metabolism and disposition: the biological fate of chemicals,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
June 2010, Toxicology and applied pharmacology,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
January 2002, Annual review of pharmacology and toxicology,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
June 2006, The Journal of pharmacology and experimental therapeutics,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
January 2016, Biochemical pharmacology,
Amélie Piton, and Claudine Rauch, and Sophie Langouet, and André Guillouzo, and Fabrice Morel
April 2009, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!